title: Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy.
abstract: Issues associated with the large-scale production of monoclonal antibodies for pharmaceutical applications are examined. The development of a commercial monoclonal antibody production process involves much more than just scaling-up the laboratory process and making it cost-effective. It involves establishing the hybridoma cell bank with cells that are free of adventitious agents such as viruses and mycoplasma, that have stability in continuous culture for antibody-production rate and cell viability, and that do not have unusual or expensive media requirements. The style and mode of operation of the bioreactor used to produce the antibody must be explored. The antibody-based product must be processed to high levels of purity, and specific contaminants such as DNA and endotoxin must be reduced to extremely low levels. Appropriate labeling or drug conjugation chemistries must also be developed. The product must be formulated so that it has performance characteristics that are stable over a reasonable period of time. Adequate test procedures must be developed to assure product purity, activity, stability, and safety on a lot-to-lot-basis. Compliance with federal regulations, guidelines, and procedures must be guaranteed. In the coming decade, it is likely that the two arms of biotechnology, hybridoma technology and recombinant DNA technology, will be used together to generate unique protein molecules. These new reagents will face the same practical considerations summarized in this review.
authors.affiliation: Research and Development Division, Centocar Inc., Malvern, PA 19355.
authors.forename: W C
authors.initials: WC
authors.lastname: Bogard
authors.forename: R T
authors.initials: RT
authors.lastname: Dean
authors.forename: Y
authors.initials: Y
authors.lastname: Deo
authors.forename: R
authors.initials: R
authors.lastname: Fuchs
authors.forename: J A
authors.initials: JA
authors.lastname: Mattis
authors.forename: A A
authors.initials: AA
authors.lastname: McLean
authors.forename: H J
authors.initials: HJ
authors.lastname: Berger
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000592:standards / Q000627:therapeutic use; D001709:Biotechnology; D006801:Humans; D006825:Hybridomas; D007120:Immunochemistry; D007167:Immunotherapy; D007553:Isotope Labeling; D011786:Quality Control; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal